Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Epratuzumab-cys-tesirine · ADCT-602

Antibody-drug conjugate · Cytotoxic, directed at CD22

Phase 1/2 Most advanced trial (none active)

1 Registered trials

What is Epratuzumab-cys-tesirine?

Epratuzumab-cys-tesirine is an antibody-drug conjugate composed of a humanized anti-CD22 monoclonal antibody conjugated to tesirine, a cathepsin B-cleavable pyrrolobenzodiazepine dimer. The antibody binds CD22 on B cells and is internalized; upon cleavage, tesirine induces DNA interstrand cross-links and inhibits DNA replication. It is studied in CD22-positive B-cell malignancies including acute lymphoblastic leukemia and Burkitt lymphoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: ADCT-602
Drug type: Antibody-drug conjugate
Targets: CD22
Mechanism: Cytotoxic, directed at CD22
Pathways: DNA cross-linking, DNA replication inhibition
Therapy area: Oncology
In trials of: ADCT
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII: 7X6143A60Y

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03698552	Phase 1/2	Blasts 5 Percent or More of Bone Marrow Nucleated Cells	Terminated	ADCT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Blasts 5 Percent or More of Bone Marrow Nucleated CellsCD22 PositivePhiladelphia Chromosome PositiveRecurrent B Acute Lymphoblastic LeukemiaRefractory B Acute Lymphoblastic Leukemia

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z